

## Oncopeptides secures regulatory approval to start Window-of-Opportunity study in glioblastoma from Norwegian authorities

Stockholm, May 19, 2026 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company specializing in difficult-to-treat cancers, today announces that its clinical trial application for the "Window-of-Opportunity" (WoO) study in glioblastoma has been formally approved in Norway. The approval was issued jointly by Direktoratet for medisinske produkter (the Norwegian Medical Products Agency, DMP and the ethics committee (REK KULMU).

The authorization, received sooner than the company had expected, means the planned study is formally approved to commence. The decision follows the [previously announced](#) regulatory agreement on the trial design and the fast-track designation granted in Norway.

The WoO study represents the first clinical evaluation of a Peptide Drug Conjugate (PDC) in glioblastoma, marking an important operational step in Oncopeptides' strategy to expand its proprietary PDC platform beyond multiple myeloma. The trial will enroll approximately 10 patients and aims to quickly verify that the company's technology successfully penetrates the human blood-brain barrier, paving the way for the subsequent clinical development of its next-generation asset, OPD5.

"The formal approval from DMP and REK is a critical milestone that allows us to move directly into the practical preparations for initiating patient recruitment in Norway," said **Sofia Heigis, CEO of Oncopeptides**. "This swift turnaround confirms the strong alignment and efficient collaboration we have experienced with the Scandinavian authorities, and we look forward to generating human clinical data in this highly underserved indication."

For more information, including a Q&A for investors, please visit [www.oncopeptides.com](http://www.oncopeptides.com)

### **For more information, please contact:**

David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)

E-mail: [ir@oncopeptides.com](mailto:ir@oncopeptides.com)

Cell phone: +46 76 229 38 68

**About Oncopeptides**

Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.

The company uses its proprietary Peptide Drug Conjugate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere.

Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE.

The company was founded in 2000, has about 80 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.

For more information see: [www.oncopeptides.com](http://www.oncopeptides.com)

**Attachments**

[Oncopeptides secures regulatory approval to start Window-of-Opportunity study in glioblastoma from Norwegian authorities](#)